Myeloma Crowd Research Initiative radio show: Thurs, Apr 16, 9:30 AM CST - Del 17p and finding a cure

I am so excited to be part of the Myeloma Crowd Research Initiative. The Myeloma Crowd Research Initiative (MCRI) is a new approach to funding cancer research; combining the skill and knowledge of leading myeloma specialists with the patient perspective and supportive patient social communities to select and fund promising research projects in myeloma. The goal of the MCRI is to find and fund a cure for multiple myeloma. And to that end, I am helping to spread the word about this important radio show to learn more about a potential way to treat (cure?) myeloma for those with the 17p deletion. If you're part of my myeloma followers and readers, I hope you tune in, learn more about how we can cure myeloma, and how you can help.

MCRI High-Risk Myeloma Series: Fighting the Devil Del17p, Dr. Orlowski, MD, PhD, MD Anderson, Thursday, April 16 @ 9:30 am CST

 Thursday, April 16, 7:30 am PST, 8:30 am MST, 9:30 am CST,10:30 am EST

Call In by Phone to Listen Live: (347) 637-2631 or Listen Live Via Computer

Deletion 17p is the most aggressive high-risk feature in myeloma. Why? New research shows that it may be because del17p is influenced by the induction of genes that would normally be repressed by p53 (a gene that regulates tumor suppression). And that del17p may also become “addicted” to these genes. Discovering these specific genes and the survivin protein may help uncover a completely new way to help del17p myeloma patients respond to myeloma treatment.

Join us for our third interview on Myeloma Crowd Radio highlighting the new Myeloma Crowd Research Initiative on high-risk myeloma. For the first time, patients and doctors are joining together to find and fund research for a patient group that is desperate for new options. 

Robert Z. Orlowski, MD, PhD, is Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, Division of Cancer Medicine, at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine and medical oncology. Dr. Orlowski earned his doctoral degree in molecular biophysics and biochemistry from Yale University and his medical degree from the Yale University School of Medicine. He completed his internship and residency in Internal Medicine at Barnes Hospital at the Washington University in St. Louis School of Medicine. Dr. Orlowski leads the SWOG committee and has published numerous book chapters, articles, and abstracts on cancer therapy, with a focus on the molecular pathogenesis of oncologic disease processes and the mechanisms of action of chemotherapeutics.